Impact Factor
3.87
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.39
1,572 total citations
h5-index
50
h5 depth signal
Cited share
66.5%
250 of 376
Total citations
1,572
Citation footprint
Metric signal
5.56
External metric anchor
Self-citation
3.1%
48 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Italy
354
Germany
311
Netherlands
268
United Kingdom
249
United States
218
Citing Fields of Research
Digestive Disorders
833
Inflammatory Bowel Diseases & Infections
386
Liver Diseases
262
Liver & Colon Cancer
204
Hepatitis
123
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,092
Articles tracked across the journal lifetime
Indexed publication set
376
250 cited publications
Last 12 months
186
15.5 publications/month
Open access share
92.5%
172 OA publications in the last year
Leading citing country
Italy
354 citing publications
Leading citing field
Digestive Disorders
833 citing publications
Latest tracked publication
18 October 2026
10 recent records available
Coverage & Indexing History
v7n1, Feb. 2019-
v1, 2013-
Active Coverage
Research Focus & Classification
Indexed Subjects
Digestive Disorders
Inflammatory Bowel Diseases & Infections
Liver Diseases
Issuing & Sponsoring Bodies
issuing body
United European Gastroenterology (Learned institution)
Broad Categories
Digestive Disorders
Inflammatory Bowel Diseases & Infections
MeSH Descriptors
Gastrointestinal Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1002/ueg2.70297
Open DOI
An App‐Based Proton Pump Inhibitor Discontinuation Tool: A Multicentre, Open‐Label, Randomised Superiority Trial
Background: Proton pump inhibitors (PPIs) are frequently used without long‐term indication. Discontinuation remains challenging because of rebound symptoms. Whether digital guidance tools improve discontinuation is unknown. We evaluated ...
02
DOI 10.1002/ueg2.70317
Open DOI
Antibiotic Stewardship in Cirrhosis: Current Recommendations and Clinical Challenges
Bacterial infections are a major cause of mortality in cirrhosis, with antibiotic prophylaxis and empirical treatment embedded in international guidelines. However, the prevalence of multidrug‐resistant organisms and the epidemiology of ...
03
DOI 10.1002/ueg2.70311
Open DOI
Symptom Profiles Compatible With Disorders of Gut‐Brain Interaction in Individuals With Coeliac Disease on a Long‐Term Gluten‐Free Diet
Background: Persistent gastrointestinal (GI) symptoms are frequently reported in patients with coeliac disease (CD). Knowledge about the role of disorders of gut‐brain interaction (DGBI) as the cause of these persistent symptoms remains ...
04
DOI 10.1002/ueg2.70310
Open DOI
Driving Digital Deprescribing—Enhancing PPI Discontinuation With an App‐Based Strategy
05
DOI 10.1002/ueg2.70307
Open DOI
Rome V Criteria for Adults: What's New and Why?
The Rome V criteria, published in 2026, represent the culmination of a 7‐year effort to refine and improve the diagnostic framework for disorders of gut–brain interaction. The revision incorporates the latest consensus guidelines and eme...
06
Background: Surveillance of low‐risk branch‐duct intraductal papillary mucinous neoplasms is usually lifelong. Criteria to stop it after 5 years of stability in older patients have not been tested outside the center that devised them, no...
07
DOI 10.1002/ueg2.70298
Open DOI
Metabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study
Background: Metabolic dysfunction‐associated steatotic disease (MASLD) affects increasing numbers of patients worldwide. The PNPLA3 p.I148M variant represents a major genetic determinant of MASLD progression. The loss‐of‐function HSD17B1...
08
DOI 10.1002/ueg2.70282
Open DOI
Aetiology‐Specific Pancreatic Enzyme Dose Requirements and Treatment Outcomes in Pancreatic Exocrine Insufficiency: The Multicentre EURO‐PEI Registry
Background: Pancreatic exocrine insufficiency (PEI) is a maldigestion syndrome leading to symptoms and nutritional deficiencies. Prospective real‐world data on pancreatic enzyme replacement therapy (PERT) dose requirements across aetiolo...
09
10
DOI 10.1002/ueg2.70296
Open DOI
Immunoglobulin a Deficiency in Coeliac Disease: A Scoping Review
Coeliac disease (CeD) and immunoglobulin A deficiency (IgAD) frequently co‐occur and share a genetic background within the HLA‐DQ2 region. Although this has been known for decades, the underlying mechanisms linking the two conditions rem...
Bibliographical & Catalog Notes
Also issued online.